Alfenta — Competitive Intelligence Brief

Alfenta (ALFENTANIL) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid Agonist. Area: Pain.

marketed Opioid Agonist Mu-type opioid receptor Pain Small molecule

Target snapshot

Alfenta (ALFENTANIL) — Rising.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Alfenta TARGET	ALFENTANIL	Rising	marketed	Opioid Agonist	Mu-type opioid receptor	1986-01-01
Lybalvi	SAMIDORPHAN	Alkermes Inc	marketed	Atypical Antipsychotic [EPC]	Mu-type opioid receptor	2021-01-01
Olinvyk	OLICERIDINE	Trevena	marketed		Mu-type opioid receptor	2020-01-01
Symproic	NALDEMEDINE	Bdsi	marketed	Opioid Antagonist	Mu-type opioid receptor	2017-01-01
Viberzi	ELUXADOLINE	AbbVie	marketed	mu-Opioid Receptor Agonist [EPC]	Mu-type opioid receptor	2015-01-01
Movantik	NALOXEGOL	Averitas	marketed	Opioid Antagonist	Mu-type opioid receptor	2014-01-01
Relistor	METHYLNALTREXONE	Salix Pharms	marketed	Opioid Antagonist	Mu-type opioid receptor	2008-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2031-08-23 — Lybalvi · 11351166 · US
• 2031-08-23 — Lybalvi · 11241425 · US
• 2031-08-23 — Lybalvi · 9126977 · US
• 2031-08-23 — Lybalvi · 10300054 · US
• 2031-08-23 — Lybalvi · 10716785 · US
• 2031-08-23 — Lybalvi · 11185541 · US
• 2031-08-23 — Lybalvi · 9517235 · US
• 2031-08-30 — Lybalvi · 9119848 · US
• 2032-02-13 — Lybalvi · 8778960 · US

Sponsor landscape (Opioid Agonist class)

1. · 4 drugs in this class
2. Rising · 2 drugs in this class
3. Pfizer · 2 drugs in this class
4. Endo · 1 drug in this class
5. Fresenius Kabi · 1 drug in this class
6. Specgx Llc · 1 drug in this class
7. Teva · 1 drug in this class
8. Bausch Health · 1 drug in this class
9. Collegium Pharm Inc · 1 drug in this class